Today Stories

Biogen signs lease for Kendall Common as part of multi-year real estate optimization plan to modernize its facilities and consolidate its Massachusetts real estate footprint New building will be designed to foster collaboration and spark innovation; Biogen plans to relocate Cambridge-based employees to the new site in 2028 CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation plan in Massachusetts. The move centralizes Biogen’s presence in Kendall Square, integrating Biogen’s research and development and technical operations teams alongside its global and North American commercial organizations into a co-locate…

Cells change shape when they are treated with drugs  New AI technology can accurately show how a cell responds to a drug based on changes to its 3D shape The tech will speed up the development of drugs for a range of diseases by around six years – as years of experiments can be cut from the current preclinical process, and drugs will be less likely to fail in clinical trials The AI tool is being further developed for patient benefit and commercial use by a new company, Sentinal 4D Scientists have developed a revolutionary AI ‘fingerprint’ technology that can accurately show how cancer cells respond to new drugs, by simply observing changes to their shape. The new technology, which has been developed by a team at The Institute of Cancer Research, London, will allow researchers to quickly…

Adoption allows ICON to take full advantage of the Medidata “Data Experience,” leveraging AI to unify data sources, standardize outputs, and reduce reconciliation efforts New York – March 20, 2025 – Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization (CRO) powered by healthcare intelligence, will immediately begin utilizing Medidata Clinical Data Studio on its studies, differentiating ICON as the first large CRO to fully infuse this technology into its clinical workflows. The integration of Clinical Data Studio into ICON’s service offerings helps unlock the full potential of the Medidata Data Experience, merging information from both M…

WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced the launch of the Thermo Scientific Vulcan™ Automated Lab, a groundbreaking solution designed to drive a new era of process development and control in semiconductor manufacturing. The seamlessly integrated system is designed to enhance productivity, increase yield and reduce operating costs for semiconductor manufacturers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318064982/en/ The rapid evolution and miniaturization of semiconductor technology is leading to unprecedented demand for atomic-scale transmission electron microscopy (TEM) metrology data. Manufacturers now face the…

The Fresenius healthcare group is continuously expanding its range of innovative products. A new laboratory and office building with a technical center called KabiLab D20 is being built at Daimlerstrasse 20 on the Fresenius campus in Bad Homburg. It will feature laboratories, a total of 90 desk-sharing workstations, meeting rooms, and storage rooms on an area totaling around 5,000 m2. The move to the new building is planned for mid-2026.  Once completed, around 70 employees from the Fresenius Kabi Business Unit Nutrition currently working in Bad Homburg and Friedberg will relocate to the new building. Among others, they are working on further development of the Fresubin enteral nutrition product portfolio as well as on a special device for producing patient-specific parenteral nutrition. P…

Acquisition includes world-leading in vivo delivery platform with potential totransform cell therapy AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer many more patients access to transformative cell therapy treatments delivered in just minutes rather than the current process which takes weeks. ENaBL uses highly targeted lentiviruses to deliver genetic instructions to specific immune cells, such as T cells, which programme them to recognise and destroy tumour cells for cancer treatment or autoreactive cells for potential use i…

Pancreatic cancer is one of the deadliest forms of cancer, largely because it’s so difficult to catch early. By the time it’s diagnosed, it’s often too late for effective treatment. But that could soon change thanks to a new discovery by Mainz Biomed and Liquid Biosciences, who have teamed up to develop a non-invasive, blood-based test that could revolutionize early detection. A Breakthrough in Early Detection The two companies have identified a set of mRNA biomarkers that could make screening for pancreatic cancer much easier and far more accurate. Using Liquid Biosciences' EMERGE platform, researchers analyzed samples from 285 subjects, including 35 pancreatic cancer patients, and found a set of biomarkers that showed an impressive 95% sensitivity and 98% specificity in detecting the dis…

Aging has long been accepted as an inevitable process, but what if we could measure the factors that accelerate it—and do something about them? That’s the idea behind InflammAge, a newly developed biomarker designed to measure systemic chronic inflammation, one of the key drivers of aging and age-related diseases. The InflammAge biomarker is at the heart of a new partnership between Bayer and Hurdle, who have joined forces to advance precision health and help consumers take more control over their aging process. Chronic inflammation has been linked to conditions like cardiovascular disease, neurodegeneration, and metabolic disorders—yet until now, there hasn’t been an easy way for individuals to measure their own inflammatory status. Aging and Inflammation: The Missing Link? Research into…

Merck & Co. (MSD outside the U.S. and Canada) has just unveiled a brand-new, cutting-edge vaccine manufacturing facility at its site in Durham, North Carolina. The $1 billion expansion is a big step forward for the company as it works to boost vaccine production and invest in the future of U.S. pharmaceutical manufacturing. This 225,000-square-foot facility isn’t just about adding more capacity—it’s about embracing the latest technology to improve efficiency and innovation. The site is equipped with advanced data analytics, generative AI, and even a digital twin—a virtual model of the manufacturing process that allows for testing and training without disrupting real-world operations. Merck has been steadily increasing its investment in U.S. manufacturing, pouring more than $12 billion…

RESEARCH TRIANGLE PARK, N.C. – March 10, 2025 – IQVIA (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions and clinical research services to the healthcare and life sciences industries, has been named to the “Leaders” category of the IDC MarketScape: Worldwide Life Science R&D Decentralized Clinical Trial Technology Solutions and Consulting Services 2024 Vendor Assessment. IDC, a global provider of market intelligence, says in its report: “Consider IQVIA when seeking deep clinical and DCT implementation strategy expertise across therapeutics areas and phases, with over 200 DCT consultants, a wide portfolio of DCT-enabling technologies and services, and expertise in providing inputs on country-wise regulatory strategy for DCT implementation and on business…

The new center will be a hub for both Roche and Genentech, bringing together expertise in Cardiovascular, Renal, and Metabolism, as well as for data science and AI specialists to drive innovation in drug discovery and development Roche will be the first to join Harvard’s Enterprise Research Campus in Allston, taking a suite in the first phase of the project’s cutting-edge lab space Starting with a lease of 30’000 square feet, Roche intends to invest over the coming years into a research and development presence with eventually up to 500 employees Roche has long standing partnerships with Harvard University and others in the region and the center will expand Roche’s and Genentech’s presence in the vibrant Boston healthcare ecosystem Basel, March 7, 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY…

Israel-Based Venture Studio Comprising AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund, Amiti Ventures and Amazon Web Services (AWS) Seeks Global Research and Technology Talent to Form New Startup Focused on: “Generative AI for Novel Target Combinations”. REHOVOT, Israel and HEIDELBERG, Germany, March 3, 2025. AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced today the launch of its latest global call for applications to identify scientific founders: computational biologists, biomedical scientists, and AI experts to form a new startup at AION Labs’ headquarters in Rehovot, Israel. AION Labs’ next startup will focus on de…

RESEARCH TRIANGLE PARK, N.C.– March 4, 2025 – IQVIA Laboratories, a leading global drug discovery and development laboratory services organization, announces the launch of Site Lab Navigator, an advanced suite of solutions that automates and streamlines lab workflows for clinical trial sponsors and investigator sites. At the core of Site Lab Navigator is a new, innovative e-Requisition solution, which allows investigator sites to submit requisitions and manage lab specimens electronically, eliminating the need for manual, paper-based processes. This reduces administrative burden, minimizes errors, drives compliance and improves study execution for both sponsors and investigator sites. IQVIA Laboratories’ e-Requisition solution within the Site Lab Navigator suite of applications is a unique…

Acquisition to expand Interventional Cardiology Therapies offerings with ultrasound-based renal denervation therapy for treatment of hypertension MARLBOROUGH, Mass., March 3, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire SoniVie Ltd., a privately held medical device company that has developed the TIVUS™ Intravascular Ultrasound System. An investigational technology, the TIVUS system is designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation (RDN) for hypertension. Closely associated with overactivity of the sympathetic nervous system, hypertension is a leading risk factor for cardiovascular disease, with treatment shown to re…

Additional investment and resources will accelerate Biocomposites’ international expansion and innovation in products for use in infection management HELLERUP, DENMARK, LONDON and KEELE, UK – 3 March 2025 – Novo Holdings and TA Associates ("TA"), announced today that the parties have entered into an agreement for Novo Holdings to make an investment in Biocomposites (“the Company”), an international medical devices company that engineers, manufactures and markets leading products for use in infection management in bone and soft tissue. As part of the transaction TA, Biocomposites’ majority shareholder since 2017, will reinvest in the Company alongside new investor Novo Holdings and Biocomposites’ management. The transaction gives TA and Novo Holdings shared control of Biocomposites. Headqua…

The Cambridge Festival is returning from March 19 to April 4 with a series of events that bring together cutting-edge health research and the latest innovations in medical science. This year's health theme comes at a pivotal moment, as global health challenges such as ageing populations, chronic disease and cancer diagnosis continue to drive scientific inquiry and public debate. Against this backdrop, the Festival provides a platform to engage the public with pioneering research from some of the brightest minds in health and medicine. The Festival offers almost 400 mostly free events across multiple themes, including environment, society, and discovery, with health research at the forefront. Visitors can attend more than 130 events focussed on this theme, many designed to demystify the sci…

Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America The company's plans represent the largest pharmaceutical manufacturing investment in U.S. history  INDIANAPOLIS, Feb. 26, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced at a press conference in Washington, D.C., plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States. This brings the company's total U.S. capital expansion commitments to more than $50 billion since 2020. Three of the future U.S. sites announced today will focus on manufacturing active pharmaceutical ingredients (API), reshoring critical capabilities of…

New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever  GALWAY, Ireland, Feb. 24, 2025 /PRNewswire(opens new window)/ -- For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) approval of BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI). There is no cure for debilitating neurological conditions like Parkinson's, however, deep brain stimulation (DBS) has been transforming the lives of people with Parkinson's and other neurological disorders for more than 30 years. DBS is similar to a ca…

RESEARCH TRIANGLE PARK, N.C. – February 24, 2025 – IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences and healthcare industries, today announced that IQVIA AI Assistant has been awarded a 2024 PM360 Innovation Award in the Artificial Intelligence category. Launched in September 2024, IQVIA AI Assistant revolutionizes insight generation by providing rapid, relevant and precise answers to complex business questions. Using a conversational interface with advanced data science, it makes complex analytics accessible to a wide variety of users and provides near real-time insights. IQVIA AI Assistant builds upon IQVIA’s decade of experience in artificial intelligence and developing Healthcare-grade AI™, a pro…

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of gastrointestinal stromal tumours (GIST). As announced previously1, the acquisition includes lead molecule IDRX-42, an investigational, highly selective tyrosine kinase inhibitor (TKI) that is designed to improve outcomes for patients with GIST. IDRX-42 has demonstrated activity against all clinically relevant primary and secondary KIT mutations, a key medical need in current GIST treatment. GIST typically presents in the gastrointestinal (GI) tract with 80% of cases driven by mutations in the KIT gene that lead to the growth, proliferation, and survival of tumour cells…